MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

A Potentially Revolutionary Heart Failure Treatment

    Arrow  backProcyrion Aortix

There are estimated to be more than 2 million patients with chronic heart failure who are no longer served well by their drug regimen, yet aren't considered sick enough for an invasive surgery to receive a transplant or left ventricular assist device (LVAD). Procyrion, a Houston, TX, company that won MD+DI's 2016 Medtech Startup Showdown is developing the Aortix device for these patients. The tiny pump will be delivered via transfemoral catheter to sit in the patient's descending thoracic aorta--a location that reduces the risk of valve damage, blood flow issues within the heart, and thrombotic stroke--and will employ fluid entrainment to accelerate blood flow, increasing the heart's efficiency. Patients are expected to be able to walk around while implanted with the Aortix, a feature that may help recovery and reduce comorbidities.

Read the full MD+DI story.

And find out the role motors played in enabling the device.

Continue >>

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.